<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1366" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1366/" /><meta name="ncbi_pagename" content="Thanatophoric Dysplasia - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Thanatophoric Dysplasia - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Thanatophoric Dysplasia" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2013/09/12" /><meta name="citation_author" content="Barbara Karczeski" /><meta name="citation_author" content="Garry R Cutting" /><meta name="citation_pmid" content="20301540" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1366/" /><meta name="citation_keywords" content="Fibroblast growth factor receptor 3" /><meta name="citation_keywords" content="FGFR3" /><meta name="citation_keywords" content="Thanatophoric Dysplasia" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Thanatophoric Dysplasia" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Barbara Karczeski" /><meta name="DC.Contributor" content="Garry R Cutting" /><meta name="DC.Date" content="2013/09/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1366/" /><meta name="description" content="Thanatophoric dysplasia (TD) is a short-limb dwarfism syndrome that is usually lethal in the perinatal period. TD is divided into type I, characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity (Kleeblattschädel) of varying severity; and type II, characterized by micromelia with straight femurs and uniform presence of moderate-to-severe cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported." /><meta name="og:title" content="Thanatophoric Dysplasia" /><meta name="og:type" content="book" /><meta name="og:description" content="Thanatophoric dysplasia (TD) is a short-limb dwarfism syndrome that is usually lethal in the perinatal period. TD is divided into type I, characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity (Kleeblattschädel) of varying severity; and type II, characterized by micromelia with straight femurs and uniform presence of moderate-to-severe cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most affected infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1366/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/td/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1366/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C471AE0409E6100000000023500C8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1366_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1366_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/tetra-amelia/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/trma/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1366_"><span class="title" itemprop="name">Thanatophoric Dysplasia</span></h1><p class="contrib-group"><span itemprop="author">Barbara Karczeski</span>, MS, MA and <span itemprop="author">Garry R Cutting</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK1366_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1366_ai__"><div class="contrib half_rhythm"><span itemprop="author">Barbara Karczeski</span>, MS, MA<div class="affiliation small">DNA Diagnostic Laboratory<br />Johns Hopkins University<br />Baltimore, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.imhj@sezcrakb" class="oemail">ude.imhj@sezcrakb</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Garry R Cutting</span>, MD<div class="affiliation small">DNA Diagnostic Laboratory<br />Johns Hopkins University<br />Baltimore, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.imhj@gnittucg" class="oemail">ude.imhj@gnittucg</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">May 21, 2004</span>; Last Update: <span itemprop="dateModified">September 12, 2013</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="td.Summary" itemprop="description"><h2 id="_td_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Thanatophoric dysplasia (TD) is a short-limb dwarfism syndrome that is usually lethal in the perinatal period. TD is divided into type I, characterized by micromelia with bowed femurs and, uncommonly, the presence of cloverleaf skull deformity (<i>Kleeblattsch&#x000e4;del</i>) of varying severity; and type II, characterized by micromelia with straight femurs and uniform presence of moderate-to-severe cloverleaf skull deformity. Other features common to type I and type II include: short ribs, narrow thorax, macrocephaly, distinctive facial features, brachydactyly, hypotonia, and redundant skin folds along the limbs. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants die of respiratory insufficiency shortly after birth. Rare long-term survivors have been reported.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>Diagnosis of TD is based on clinical examination and/or prenatal ultrasound examination and radiologic studies. Characteristic histopathology is also present. <i>FGFR3</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is known to cause TD. Up to 99% of pathogenic variants causing TD type I and more than 99% of pathogenic variants causing TD type II can be identified through <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>FGFR3</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management focuses on the parents' wishes for provision of comfort-care for the newborn. Newborns require respiratory support (with tracheostomy and ventilation) to survive. Anesthetic management may include: intubation with a flexible fiberoptic scope with the cervical spine in a neutral position; use of evoked potential monitoring during the procedure; and avoidance of volatile anesthetic agents and muscle relaxants that may interfere with evoked potential recordings. Other treatment measures may include: antiepileptic drugs to control seizures, shunt placement for hydrocephaly, suboccipital decompression for relief of craniocervical junction constriction, and hearing aids.</p><p><i>Surveillance</i>: Long-term survivors need neurologic, orthopedic, and audiologic evaluations, CT to monitor for craniocervical constriction, and EEG to monitor for seizure activity.</p><p><i>Pregnancy management</i>: When TD is diagnosed prenatally, treatment goals are to avoid potential pregnancy complications including prematurity, polyhydramnios, malpresentation, and delivery complications from macrocephaly and/or a flexed and rigid neck; cephalocentesis and cesarean section may be considered to avoid maternal complications.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>TD is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; the majority of probands have <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> of <i>FGFR3</i>. Risk of recurrence for parents who have had one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child is not significantly increased over that of the general population. Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in healthy parents, although not previously reported, remains a theoretic possibility. Prenatal diagnosis is possible by ultrasound examination and <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div></div><div id="td.Diagnosis"><h2 id="_td_Diagnosis_">Diagnosis</h2><div id="td.Clinical_Diagnosis"><h3>Clinical Diagnosis</h3><p>Thanatophoric dysplasia (TD) is one of the short-limb dwarfism conditions suspected when significantly shortened long bones and a narrow thorax are detected prenatally or neonatally, especially when perinatal death occurs.</p><p><b>Prenatal ultrasound examination</b> [<a class="bk_pop" href="#td.REF.de_biasio.2000.835">De Biasio et al 2000</a>, <a class="bk_pop" href="#td.REF.chen.2001.89">Chen et al 2001</a>, <a class="bk_pop" href="#td.REF.ferreira.2004.241">Ferreira et al 2004</a>, <a class="bk_pop" href="#td.REF.de_biasio.2005.426">De Biasio et al 2005</a>, <a class="bk_pop" href="#td.REF.tonni.2010.314">Tonni et al 2010</a>, <a class="bk_pop" href="#td.REF.khalil.2011.115">Khalil et al 2011</a>, <a class="bk_pop" href="#td.REF.mart_nezfr_as.2011.197">Mart&#x000ed;nez-Fr&#x000ed;as et al 2011</a>] findings by trimester include the following:</p><ul><li class="half_rhythm"><div><b>First trimester</b></div><ul><li class="half_rhythm"><div>Shortening of the long bones, possibly visible as early as 12 to 14 weeks' gestation</div></li><li class="half_rhythm"><div>Increased nuchal translucency</div></li><li class="half_rhythm"><div>Reverse flow in the ductus venosus (one case report), possibly the result of the narrow thorax compressing vascular flow</div></li></ul></li><li class="half_rhythm"><div><b>Second/third trimester</b></div><ul><li class="half_rhythm"><div>Growth deficiency with limb length below fifth centile recognizable by 20 weeks' gestation</div></li><li class="half_rhythm"><div>Well-ossified spine and skull</div></li><li class="half_rhythm"><div>Platyspondyly</div></li><li class="half_rhythm"><div>Ventriculomegaly</div></li><li class="half_rhythm"><div>Narrow chest cavity with short ribs</div></li><li class="half_rhythm"><div>Polyhydramnios</div></li><li class="half_rhythm"><div>Bowed femurs (TD type I)</div></li><li class="half_rhythm"><div>Encephalocele (infrequently; other brain abnormalities also described)</div></li><li class="half_rhythm"><div>Cloverleaf skull (<i>Kleeblattsch&#x000e4;del</i>) (often in TD type II; occasionally in TD type I) and/or relative macrocephaly</div></li></ul></li></ul><p>Note: Although identification of a lethal skeletal dysplasia in the second trimester is often straightforward, establishing the specific diagnosis can be difficult [<a class="bk_pop" href="#td.REF.parilla.2003.255">Parilla et al 2003</a>, <a class="bk_pop" href="#td.REF.krakow.2008.1917">Krakow et al 2008</a>, <a class="bk_pop" href="#td.REF.schramm.2009.160">Schramm et al 2009</a>]. Ultrasound examination or review of the ultrasound films by an OB/geneticist may be most helpful in making a specific diagnosis prenatally. A three-dimensional ultrasound examination may also aid in visualizing facial features and other soft tissue findings of TD [<a class="bk_pop" href="#td.REF.chen.2001.89">Chen et al 2001</a>].</p><p><b>Postnatal physical examination</b> [<a class="bk_pop" href="#td.REF.lemyre.1999.185">Lemyre et al 1999</a>, <a class="bk_pop" href="#td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</a>, <a class="bk_pop" href="#td.REF.de_biasio.2000.835">De Biasio et al 2000</a>]:</p><ul><li class="half_rhythm"><div>Macrocephaly</div></li><li class="half_rhythm"><div>Large anterior fontanelle</div></li><li class="half_rhythm"><div>Frontal bossing, flat facies with a depressed nasal bridge, ocular proptosis</div></li><li class="half_rhythm"><div>Marked shortening of the limbs (micromelia)</div></li><li class="half_rhythm"><div>Trident hand with brachydactyly</div></li><li class="half_rhythm"><div>Redundant skin folds</div></li><li class="half_rhythm"><div>Narrow bell-shaped thorax with short ribs and protuberant abdomen</div></li><li class="half_rhythm"><div>Relatively normal trunk length</div></li><li class="half_rhythm"><div>Generalized hypotonia</div></li><li class="half_rhythm"><div>Bowed femurs (TD type I)</div></li><li class="half_rhythm"><div>Cloverleaf skull (always in TD type II; sometimes in TD type I)</div></li></ul><p><b>Radiographs/other imaging studies</b> [<a class="bk_pop" href="#td.REF.wilcox.1998.274">Wilcox et al 1998</a>, <a class="bk_pop" href="#td.REF.lemyre.1999.185">Lemyre et al 1999</a>]:</p><ul><li class="half_rhythm"><div>Rhizomelic shortening of the long bones</div></li><li class="half_rhythm"><div>Irregular metaphyses of the long bones</div></li><li class="half_rhythm"><div>Platyspondyly</div></li><li class="half_rhythm"><div>Small foramen magnum with brain stem compression</div></li><li class="half_rhythm"><div>CNS abnormalities including temporal lobe malformations, hydrocephaly, brain stem hypoplasia, neuronal migration abnormalities</div></li><li class="half_rhythm"><div>Bowed femurs (TD type I)</div></li><li class="half_rhythm"><div>Cloverleaf skull (always in TD type II; sometimes in TD type I)</div></li></ul><p><b>Other reported findings</b> include cardiac defects (patent ductus arteriosis and atrial septal defect) and renal abnormalities.</p></div><div id="td.Molecular_Genetic_Testing"><h3>Molecular Genetic Testing</h3><p><b>Gene.</b>
<i>FGFR3</i> is the only <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which mutation is known to cause TD type I and TD type II. The <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Lys650Glu</a> has been identified in all individuals with TD type II [<a class="bk_pop" href="#td.REF.bellus.2000.1411">Bellus et al 2000</a>].</p><p><b>Clinical testing</b></p><ul><li class="half_rhythm"><div><b>Sequence analysis of the entire</b>
<b><i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a></b> is not clinically indicated for TD as there is no increase in test <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a>, and test specificity may decrease as a result of the finding of novel variants of uncertain clinical significance.</div></li></ul><div id="td.T.molecular_genetic_testing_used_in_t" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Thanatophoric Dysplasia</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1366/table/td.T.molecular_genetic_testing_used_in_t/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__td.T.molecular_genetic_testing_used_in_t_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" style="text-align:left;vertical-align:middle;">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th><th id="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Variant Detection Frequency by Method and Phenotype&#x000a0;<sup>3</sup></th></tr><tr><th headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4" id="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">TD Type I</th><th headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4" id="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">TD Type II</th></tr></thead><tbody><tr><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>FGFR3</i></td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Targeted analysis for pathogenic variants; <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of select regions</td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reported variants&#x000a0;<sup>4,&#x000a0;5</sup></td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Up to 99%</td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td></tr><tr><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Lys650Glu</a></td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td></tr><tr><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis of entire <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>&#x000a0;<sup>6,</sup>&#x000a0;<sup>7</sup></td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>FGFR3</i> sequence variants</td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td><td headers="hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_1_4 hd_h_td.T.molecular_genetic_testing_used_in_t_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;99%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">NA = not applicable</p></div></dd><dt>1. </dt><dd><div id="td.TF.1.1"><p class="no_margin">See <a href="/books/NBK1366/#td.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="td.TF.1.2"><p class="no_margin">See <a href="#td.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants.</p></div></dd><dt>3. </dt><dd><div id="td.TF.1.3"><p class="no_margin">The ability of the test method used to detect a variant that is present in the indicated <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a></p></div></dd><dt>4. </dt><dd><div id="td.TF.1.4"><p class="no_margin">Some labs do not test for <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Lys650Met</a>, the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> that causes both <i>s</i>evere <i>a</i>chondroplasia with <i>d</i>evelopmental <i>d</i>elay and <i>a</i>canthosis <i>n</i>igricans (SADDAN) and thanatophoric dysplasia, type I [<a class="bk_pop" href="#td.REF.bellus.2000.1411">Bellus et al 2000</a>].</p></div></dd><dt>5. </dt><dd><div id="td.TF.1.5"><p class="no_margin">Variant panels and detection rates may vary among laboratories. Selected exons of <i>FGFR3</i> previously reported to contain pathogenic variants: for TD type I, <i>FGFR3</i> exons 7, 10, 15, and 19; for TD type II, <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 15.</p></div></dd><dt>6. </dt><dd><div id="td.TF.1.6"><p class="no_margin">Not clinically indicated; see <a href="#td.Molecular_Genetic_Testing">Molecular Genetic Testing</a>, <b>Sequence analysis of the entire <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a></b><i>.</i></p></div></dd><dt>7. </dt><dd><div id="td.TF.1.7"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd></dl></div></div></div></div><div id="td.Testing_Strategy"><h3>Testing Strategy</h3><p><b>To confirm/establish the diagnosis</b> when TD is suspected based on findings of pre- or postnatal examination:</p><ul><li class="half_rhythm"><div>If TD type II is suspected on the basis of straight femurs and cloverleaf skull, targeted testing for the <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Lys650Glu</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may be an appropriate first step in diagnostic testing.</div></li><li class="half_rhythm"><div>Otherwise, <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> of select exons may considered, followed by full <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sequencing if no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified.</div></li></ul><p><b>Prenatal diagnosis</b> for at-risk pregnancies requires prior identification of the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family.</p><p>Note: Some families with a previous child with confirmed TD may opt for <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (even though <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> is not significantly elevated and ultrasound examination can detect TD early in pregnancy).</p></div></div><div id="td.Clinical_Characteristics"><h2 id="_td_Clinical_Characteristics_">Clinical Characteristics</h2><div id="td.Clinical_Description"><h3>Clinical Description</h3><p>Thanatophoric dysplasia (TD) types I and II are diagnosed prenatally or in the immediate newborn period. Both subtypes are considered lethal skeletal dysplasias; most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> infants die of respiratory insufficiency in the first hours or days of life. Respiratory insufficiency may be secondary to a small chest cavity and lung hypoplasia, compression of the brain stem by the small foramen magnum, or a combination of both. Some affected children have survived into childhood with aggressive ventilatory support.</p><p><b>Long-term survivors.</b> The clinical findings of two children (a male aged 4.75 years and a female aged 3.7 years at last follow up) were summarized by <a class="bk_pop" href="#td.REF.macdonald.1989.508">MacDonald et al [1989]</a>. Both had birth length and weight below the third centile. Head circumference was at the 97th centile. In both, growth plateaued after age ten months:</p><ul><li class="half_rhythm"><div>The male required ventilatory support at birth and tracheostomy at age three months. Other clinical findings included: micromelia, redundant skin folds, hydrocephalus diagnosed at age two months, seizure activity at age three months, a small foramen magnum with compression of the brain stem diagnosed at age 15 months, and little developmental progress after age 20 months. Platyspondyly, bowed tubular bones, and splayed ribs were noted radiographically. Head CT showed abnormal differentiation of the white and grey matter of the brain.</div></li><li class="half_rhythm"><div>The female required ventilatory support beginning at age two months. A small foramen magnum with brain stem compression was diagnosed at age two months, and hydrocephaly was diagnosed at age four months. Bilateral hearing loss and progressive lack of ossification of the caudal spine were noted at age 3.7 years. She had two words and knew some sign language.</div></li></ul><p>A male age nine years with the common TD type I-causing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Arg248Cys</a> was reported. Birth weight was at the 50th centile (normal growth charts); birth length was more than four SD below the mean (achondroplasia growth charts). He required tracheostomy and ventilatory support. At age three years, he demonstrated stable ventriculomegaly, craniosynostosis, and little limb growth. By age eight years, he had seizures, bilateral hearing loss, kyphosis, and both joint hypermobility and joint contractures. At age nine years, the limbs had grown little; and radiologic findings were similar to those expected in TD. Extensive acanthosis nigricans was present. He was severely developmentally delayed and had no language. Final height was estimated to be 80-90 cm (32-35 inches).</p><p><a class="bk_pop" href="#td.REF.thompson.2011.92">Thompson et al [2011]</a> described an 11-month (at time of publication) survivor who required suboccipital decompression in infancy due to clonus and decreased limb movements secondary to a narrow foramen magnum.</p><p><b>Mosaicism.</b> A female age 47 years who was mosaic for the common TD type I-causing <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Arg248Cys had asymmetric limb length, bilateral <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hip dislocation, focal areas of bone bowing, an "S"-shaped humerus, extensive acanthosis nigricans, redundant skin folds along the length of the limbs, and flexion deformities of the knees and elbows [<a class="bk_pop" href="#td.REF.hyland.2003.157">Hyland et al 2003</a>]. She had delayed developmental milestones as a child. Academic achievements were below those of healthy sibs, but she is able to read and write and is employed as a factory worker. Her only pregnancy ended with the stillbirth at 30 weeks' gestation of a male with a short-limb skeletal dysplasia and pulmonary hypoplasia.</p><p><a class="bk_pop" href="#td.REF.takagi.2012.247">Takagi et al [2012]</a> described an individual with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Arg248Cys</a> substitution in <i>FGFR3</i> (a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> which typically results in TD type I) who presented with features of atypical achondroplasia.</p></div><div id="td.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>TD types I and II do not share common <i>FGFR3</i> pathogenic variants [<a class="bk_pop" href="#td.REF.wilcox.1998.274">Wilcox et al 1998</a>, <a class="bk_pop" href="#td.REF.brodie.1999.476">Brodie et al 1999</a>, <a class="bk_pop" href="#td.REF.camera.2001.277">Camera et al 2001</a>].</p><p>No strong <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation for <i>FGFR3</i> pathogenic variants exists within TD type I and TD type II, respectively. Variability in the TD phenotype has been described and, with the exception of the proposed <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>-dependent differences in severity of endochondral disturbance in the long bones [<a class="bk_pop" href="#td.REF.bellus.2000.1411">Bellus et al 2000</a>], is not variant specific.</p><p>Cases of TD caused by two <i>FGFR3</i> pathogenic variants <i>in</i>
<a class="def" href="/books/n/gene/glossary/def-item/cis/"><i>cis</i></a> have been reported [<a class="bk_pop" href="#td.REF.pannier.2009.1296">Pannier et al 2009</a>, <a class="bk_pop" href="#td.REF.marquisnicholson.2013.80">Marquis-Nicholson et al 2013</a>]. In both cases one <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was previously reported to be associated with hypochondroplasia and one was a novel pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variant.</p><p>Other clinical disorders rarely involve <i>FGFR3</i> pathogenic variants previously identified in individuals with TD (see <a href="#td.Genetically_Related_Allelic_Disorders">Genetically Related Disorders</a>).</p></div><div id="td.Penetrance"><h3>Penetrance</h3><p>The <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> of <i>FGFR3</i> pathogenic variants is 100%.</p></div><div id="td.Anticipation"><h3>Anticipation</h3><p>Anticipation is not observed.</p></div><div id="td.Nomenclature"><h3>Nomenclature</h3><p>TD was originally described as thanatophoric dwarfism, a term no longer in use.</p><p>Although considered to be one of the platyspondylic lethal skeletal dysplasias, the term PLSD used with a specific subtype (San Diego, Luton, or Torrance) would be considered a separate clinical entity from TD types I and II. The PLSDs are sometimes referred to as "TD variants" because of their clinical similarity.</p></div><div id="td.Prevalence"><h3>Prevalence</h3><p>The incidence of TD was originally estimated at 1:20,000 to 1:50,000 births [<a class="bk_pop" href="#td.REF.wilcox.1998.274">Wilcox et al 1998</a>, <a class="bk_pop" href="#td.REF.baitner.2000.594">Baitner et al 2000</a>, <a class="bk_pop" href="#td.REF.chen.2001.89">Chen et al 2001</a>]. Recent studies suggest that the incidence is actually closer to 1:20,000 [<a class="bk_pop" href="#td.REF.barbosabuck.2012.1038">Barbosa-Buck et al 2012</a>] or higher (1:12,000 in Northern Ireland) in a population with optimized ascertainment [<a class="bk_pop" href="#td.REF.donnelly.2010.114">Donnelly et al 2010</a>].</p></div></div><div id="td.Genetically_Related_Allelic_Disorders"><h2 id="_td_Genetically_Related_Allelic_Disorders_">Genetically Related (Allelic) Disorders</h2><p><i>FGFR3</i> pathogenic variants have been identified in several disorders with highly variable phenotypes:</p><ul><li class="half_rhythm"><div><a href="/books/n/gene/achondroplasia/"><b>Achondroplasia</b></a><b>.</b> The causative <i>FGFR3</i> variants p.Gly380Arg and p.Gly375Cys have been identified in nearly 100% of individuals [<a class="bk_pop" href="#td.REF.camera.2001.277">Camera et al 2001</a>]. <a class="bk_pop" href="#td.REF.camera.2001.277">Camera et al [2001]</a> reported an individual with the common TD type I-causing variant p.Arg248Cys and a clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of achondroplasia. Although <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> remains a possible explanation for the mild phenotype, no mosaicism was identified in either buccal mucosal cells or blood.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/hypochondroplasia/"><b>Hypochondroplasia</b></a><b>.</b> Although <i>FGFR3</i> pathogenic variants are identifiable in about 80% of individuals with hypochondroplasia, several families are not linked to <i>FGFR3</i>; therefore, genetic heterogeneity is likely [<a class="bk_pop" href="#td.REF.camera.2001.277">Camera et al 2001</a>].</div></li><li class="half_rhythm"><div><b>SADDAN</b> (<i>s</i>evere <i>a</i>chondroplasia with <i>d</i>evelopmental <i>d</i>elay and <i>a</i>canthosis <i>n</i>igricans) is caused by <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Lys650Met [<a class="bk_pop" href="#td.REF.bellus.1999.53">Bellus et al 1999</a>, <a class="bk_pop" href="#td.REF.tavormina.1999.722">Tavormina et al 1999</a>].</div></li><li class="half_rhythm"><div><b>Crouzon syndrome with acanthosis nigricans</b> (see <a href="/books/n/gene/craniosynostosis/"><i>FGFR</i>-Related Craniosynostosis Syndromes</a>) is caused by <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Ala391Glu.</div></li><li class="half_rhythm"><div><b>Familial acanthosis nigricans.</b> A p.Lys650Thr <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified in several <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> acanthosis nigricans and short stature.</div></li><li class="half_rhythm"><div><b>Nonsyndromic coronal synostosis</b> (<a href="/books/n/gene/muenke/">Muenke syndrome</a>) (see also <a href="/books/n/gene/craniosynostosis/"><i>FGFR</i>-Related Craniosynostosis Syndromes</a>) is characterized by a p.Pro250Arg <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FGFR3</i> [<a class="bk_pop" href="#td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</a>, <a class="bk_pop" href="#td.REF.mcintosh.2000.85">McIntosh et al 2000</a>].</div></li><li class="half_rhythm"><div><b>Platyspondylic lethal skeletal dysplasia, San Diego type (PLSD-SD).</b> Although PLSD-SD has been described as a distinct clinical entity, much phenotypic overlap exists with TD. Both disorders feature short, bowed long bones, platyspondyly, and short ribs. In PLSD-SD, metaphyseal flaring and chondrocyte abnormalities can be less severe [<a class="bk_pop" href="#td.REF.brodie.1999.476">Brodie et al 1999</a>]. An important histologic difference is the consistent presence in the chondrocytes in PLSD-SD of dilated loops/inclusion bodies in the endoplasmic reticulum, which are not typical in TD. All individuals with PLSD-SD studied by <a class="bk_pop" href="#td.REF.brodie.1999.476">Brodie et al [1999]</a> had <i>FGFR3</i> pathogenic variants previously reported in association with TD type I.</div></li><li class="half_rhythm"><div><b>LADD syndrome</b> (<i>l</i>acrimo-<i>a</i>uriculo-<i>d</i>ento-<i>d</i>igital syndrome, Levy Hollister syndrome). <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> p.Asp513Asn has been reported in one family with this syndrome [<a class="bk_pop" href="#td.REF.rohmann.2006.414">Rohmann et al 2006</a>].</div></li></ul></div><div id="td.Differential_Diagnosis"><h2 id="_td_Differential_Diagnosis_">Differential Diagnosis</h2><p>Disorders to consider in the differential diagnosis of thanatophoric dysplasia (TD) [<a class="bk_pop" href="#td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</a>, <a class="bk_pop" href="#td.REF.de_biasio.2000.835">De Biasio et al 2000</a>, <a class="bk_pop" href="#td.REF.lee.2002.113">Lee et al 2002</a>, <a class="bk_pop" href="#td.REF.neumann.2003.786">Neumann et al 2003</a>]:</p><ul><li class="half_rhythm"><div><b>Homozygous</b>
<a href="/books/n/gene/achondroplasia/"><b>achondroplasia</b></a> has a similar clinical presentation and should be a part of the differential diagnosis when both parents have achondroplasia.</div></li><li class="half_rhythm"><div><b>Achondrogenesis,</b> including <b>achondrogenesis type IA,</b>
<a href="/books/n/gene/achon1b/"><b>type IB</b></a><b>,</b> and <b>type II, Schneckenbecken dysplasia.</b> Clinical features of achondrogenesis type 1B (ACG1B) include extremely short limbs with short fingers and toes, hypoplasia of the thorax, protuberant abdomen, and hydropic fetal appearance caused by the abundance of soft tissue relative to the short skeleton. The face is flat, the neck is short, and the soft tissue of the neck may be thickened. The vertebral bodies show no or minimal ossification. The ribs are short. The iliac bones are ossified only in their upper part, giving a crescent-shaped, "paraglider-like" appearance on x-ray. The ischia are usually not ossified. The tubular bones are shortened such that no major axis can be recognized; metaphyseal spurring gives the appearance of a "thorn apple." The phalanges are poorly ossified and therefore only rarely identified in x-rays. Death occurs prenatally or shortly after birth. The final diagnosis should be based on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>SLC26A2</i> (<i>DTDST</i>). The presence of rib fractures and the absence of ossification of vertebral pedicles may suggest ACG1A. ACG2 shows more severe underossification of the vertebral bodies than ACG1B, in addition to quite typical configuration of the iliac bones with concave medial and inferior borders, and non-ossification of the ischial and pubic bones. The <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> in which pathogenic variants occur to cause ACG1A is <i>TRIP11</i>; ACG2 is caused by <i>COL2A1</i> pathogenic variants.</div></li><li class="half_rhythm"><div><b>SADDAN (severe achondroplasia with developmental delay and acanthosis nigricans)</b> (see <a href="/books/n/gene/achondroplasia/">Achondroplasia</a>) is a rare disorder characterized by extremely short stature, severe tibial bowing, profound developmental delay, and acanthosis nigricans. Unlike individuals with TD, those with SADDAN dysplasia survive past infancy. The three unrelated individuals with this <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> who have been observed to date have had obstructive apnea but have not required prolonged mechanical ventilation. An <i>FGFR3</i> p.Lys650Met <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in all three individuals.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/oi/"><b>Osteogenesis imperfecta</b></a>
<b>type II (OI type II).</b> Osteogenesis imperfecta (OI) is characterized by fractures with minimal or absent trauma. Clinically, OI was classified into four types; the type most reminiscent of TD is OI type II (the perinatal lethal form). This disorder is characterized by extremely short stature, dark blue sclerae, severe limb deformity, multiple fractures of ribs, minimal calvarial mineralization, platyspondyly, and marked compression of long bones. Biochemical testing (i.e., analysis of the structure and quantity of type I collagen synthesized in vitro by cultured dermal fibroblasts) detects abnormalities in 98% of individuals with OI type II. Most individuals with OI type II have pathogenic variants in either <i>COL1A1</i> or <i>COL1A2</i>, the two genes encoding type I collagen. Osteogenesis imperfecta type II is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</div></li><li class="half_rhythm"><div><b>Short rib-polydactyly syndromes</b> are short-limb dwarfisms with narrow thorax. They are currently classified into four subtypes that may or may not be proven to be distinct clinical entities. Findings distinguishing these disorders from TD include polydactyly and/or syndactyly of the hands or feet. Type I (Saldino-Noonan type) features cardiac defects. Type II (Majewski type) may have cleft lip, cleft palate, ambiguous genitalia, and renal abnormalities. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/campo-dysp/"><b>Campomelic dysplasia</b></a>
<b>(CD)</b> is a prenatal-onset, usually lethal skeletal dysplasia with narrow thorax. Individuals with CD have bowed tibiae, skin dimples, and hypoplastic scapulae. Many individuals with CD have 11 pairs of ribs. The tubular bones are poorly developed and show immature ossification. <a class="bk_pop" href="#td.REF.mansour.1995.415">Mansour et al [1995]</a> found that up to 75% of individuals with CD with a 46,XY <a class="def" href="/books/n/gene/glossary/def-item/karyotype/">karyotype</a> have either female external genitalia or ambiguous genitalia. Campomelic dysplasia is caused by <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a>, <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> pathogenic variants in <i>SOX9</i> or chromosomal rearrangements upstream or downstream of <i>SOX9</i> on <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 17.</div></li><li class="half_rhythm"><div><a href="/books/n/gene/rcdp/"><b>Rhizomelic chondrodysplasia punctata</b></a>
<b>(RCDP)</b> is a disorder of peroxisome biogenesis. Type 1 (RCDP1), the classic type, is characterized by rhizomelia (shortening of the humerus and to a lesser degree the femur), punctate calcifications in cartilage with epiphyseal and metaphyseal abnormalities (chondrodysplasia punctata), coronal clefts of the vertebral bodies, and cataracts that are usually present at birth or appear in the first few months of life. Birth weight, length, and head circumference are often at the lower range of normal; postnatal growth deficiency is profound. Intellectual disability is severe, and the majority of children develop seizures. Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children do not survive the first decade of life; a proportion die in the neonatal period. The diagnosis of RCDP1 is confirmed by the demonstration of deficiency of red blood cell plasmalogens, increased plasma concentration of phytanic acid, and deficiencies in plasmalogen biosynthesis and phytanic acid oxidation in cultured skin fibroblasts. The disorder is caused by pathogenic variants in <i>PEX7</i>, the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> encoding the receptor for a subset of peroxisomal matrix enzymes. A common <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is responsible in the majority. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>Asphyxiating thoracic dystrophy (Jeune thoracic dystrophy)</b> is another chondrodysplasia marked by a narrow thorax. Short stature and short limbs are noted in infancy, but survivors may manifest only mild-to-moderate short stature. Survivors commonly develop renal insufficiency and can develop liver disease. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li><li class="half_rhythm"><div><b>Platyspondylic lethal skeletal dysplasia (PLSD) &#x02013; San Diego type, Torrance type, and Luton type.</b> These short-limb dwarfism syndromes are clinically very similar to TD and have often been referred to as "TD variants." The Luton type is considered to be a mild form of the Torrance type [<a class="bk_pop" href="#td.REF.nishimura.2004.75">Nishimura et al 2004</a>]. PLSD, Torrance type is characterized by shortened long bones with ragged metaphyses, radial bowing, and wafer-like vertebrae. All subtypes can be distinguished from TD histologically by the consistent presence of dilated loops of endoplasmic reticulum in the chondrocytes. <i>FGFR3</i> pathogenic variants have been identified in PLSD, San Diego type, but not in Torrance or Luton types [<a class="bk_pop" href="#td.REF.brodie.1999.476">Brodie et al 1999</a>, <a class="bk_pop" href="#td.REF.neumann.2003.786">Neumann et al 2003</a>]. <a class="bk_pop" href="#td.REF.nishimura.2004.75">Nishimura et al [2004]</a> and <a class="bk_pop" href="#td.REF.zankl.2005.61">Zankl et al [2005]</a> identified <i>COL2A1</i> pathogenic variants in several families with PLSD, Torrance type or PLSD, Torrance-Luton type.</div></li><li class="half_rhythm"><div><b>Dyssegmental dysplasia, Silverman-Handmaker type (DDSH)</b> is a lethal disorder characterized by narrow thorax, short neck, short stature, bowed limbs, and irregular ossification of the vertebral bodies. Encephalocele and cleft palate are common. DDSH is caused by pathogenic variants in the heparan sulfate proteoglycan <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, <i>HSPG2</i> [<a class="bk_pop" href="#td.REF.arikawahirasawa.2001.254">Arikawa-Hirasawa et al 2001</a>]. Inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</div></li></ul></div><div id="td.Management"><h2 id="_td_Management_">Management</h2><div id="td.Evaluations_Following_Initial_Diagnos"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in a newborn diagnosed with thanatophoric dysplasia (TD), the following evaluations are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Assessment of respiratory status by respiratory rate and skin color; arterial blood gases may be helpful in infants who survive the immediate postnatal period.</div></li><li class="half_rhythm"><div>Assessment of the presence of hydrocephaly or other central nervous system abnormalities by CT or MRI</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and genetic counselor</div></li></ul></div><div id="td.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Management concerns are limited to the parents' desire for extreme life-support measures and provision-of-comfort care for the newborn.</p><p>Newborns require respiratory support (with tracheostomy and ventilation) to survive.</p><p>Anesthesia management concerns are described by <a class="bk_pop" href="#td.REF.thompson.2011.92">Thompson et al [2011]</a> and include:</p><ul><li class="half_rhythm"><div>Intubation with the cervical spine in a neutral position using a flexible fiber-optic scope</div></li><li class="half_rhythm"><div>Utilization of evoked potential monitoring (somatosensory evoked potentials [SEPs] and motor evoked potentials [MEPs]) during the procedure to evaluate safety during intraoperative manipulations</div></li><li class="half_rhythm"><div>Avoidance of volatile anesthetic agents and muscle relaxants which could affect the evoked potential recordings</div></li></ul><p>Other measures:</p><ul><li class="half_rhythm"><div>Medication to control seizures, as in the general population</div></li><li class="half_rhythm"><div>Shunt placement, when hydrocephaly is identified</div></li><li class="half_rhythm"><div>Suboccipital decompression for relief of craniocervical junction constriction</div></li><li class="half_rhythm"><div>Hearing aids, when hearing loss is identified</div></li></ul></div><div id="td.Surveillance"><h3>Surveillance</h3><p>The following are appropriate:</p><ul><li class="half_rhythm"><div>Routine assessment of neurologic status on physical examination</div></li><li class="half_rhythm"><div>Orthopedic evaluation upon the development of joint contractures or joint hypermobility [<a class="bk_pop" href="#td.REF.wilcox.1998.274">Wilcox et al 1998</a>]</div></li><li class="half_rhythm"><div>Audiology assessment</div></li><li class="half_rhythm"><div>CT to evaluate for craniocervical constriction in long-term survivors if respiratory insufficiency is potentially the result of compression of the brain stem at the craniocervical junction</div></li><li class="half_rhythm"><div>EEG for seizure activity</div></li></ul></div><div id="td.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>See <a href="#td.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="td.Pregnancy_Management"><h3>Pregnancy Management</h3><p>When TD has been diagnosed prenatally, potential pregnancy complications include prematurity, polyhydramnios, malpresentation, and cephalopelvic disproportion caused by macrocephaly from hydrocephalus or a flexed and rigid neck. Cephalocentesis and cesarean section may be considered to avoid maternal complications.</p><p>Management of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> pregnancy is directed by the level of parental desire for heroic life-saving measures and is often highly center-specific. It can be addressed on three levels:</p><ul><li class="half_rhythm"><div><b>Maternal.</b> Surveillance for cephalopelvic disproportion, polyhydramnios, and/or preterm labor; avoidance of emergency C-section for fetal distress</div></li><li class="half_rhythm"><div><b>Fetal.</b> Surveillance for malpresentation, periodic prenatal ultrasound monitoring of head circumference, MRI for fetal lung volume, and/or fetal stress testing</div></li><li class="half_rhythm"><div><b>Familial.</b> Establishment of a perinatal plan for assessment, care, and/or withdrawal of care after delivery</div></li></ul></div><div id="td.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="td.Genetic_Counseling"><h2 id="_td_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="td.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Thanatophoric dysplasia (TD) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner; the majority of probands have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="td.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>TD is almost always caused by a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FGFR3</i>.</div></li><li class="half_rhythm"><div>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are not <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li><li class="half_rhythm"><div>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> that included the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FGFR3</i> (<a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">p.Arg248Cys</a>) has been reported in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual [<a class="bk_pop" href="#td.REF.hyland.2003.157">Hyland et al 2003</a>]; this individual's only offspring had a lethal skeletal dysplasia. Current diagnostic techniques do not detect mosaicism for <i>FGFR3</i> pathogenic variants causing TD.</div></li><li class="half_rhythm"><div>An advanced paternal age effect has been reported [<a class="bk_pop" href="#td.REF.lemyre.1999.185">Lemyre et al 1999</a>, <a class="bk_pop" href="#td.REF.donnelly.2010.114">Donnelly et al 2010</a>].</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the proband's parents.</div></li><li class="half_rhythm"><div>Because TD generally occurs as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is small.</div></li><li class="half_rhythm"><div>Although no instances of <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in an individual without signs of a skeletal dysplasia have been reported in the literature, it remains a theoretic possibility.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>Individuals with TD do not reproduce.</div></li><li class="half_rhythm"><div>Somatic and <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>FGFR3</i> (p.Arg248Cys) has been reported in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual [<a class="bk_pop" href="#td.REF.hyland.2003.157">Hyland et al 2003</a>]; this individual's only offspring had a lethal skeletal dysplasia.</div></li></ul><p><b>Other family members of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Extended family members of the proband are not at increased risk.</p></div><div id="td.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p><b>Family planning.</b> The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="td.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High-risk pregnancies.</b> Once the <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for TD are possible.</p><p><b>Low-risk pregnancies.</b> Routine prenatal ultrasound examination may identify skeletal findings (e.g., cloverleaf skull, very short extremities, small thorax) that raise the possible diagnosis of TD in a fetus not known to be at risk. Once a lethal skeletal dysplasia is identified prenatally, it is often difficult to pinpoint a specific diagnosis. Consideration of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for <i>FGFR3</i> pathogenic variants in these situations is appropriate.</p></div></div><div id="td.Resources"><h2 id="_td_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=thanatophoricdysplasia;jsessionid=F873F2A9868B1B7B161DE2547E43C8E4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Thanatophoric Dysplasia</a></div></li><li class="half_rhythm"><div><b>Compassionate Friends</b></div><div><i>Supporting Family After a Child Dies</i></div><div>PO Box 3696</div><div>Oak Brook IL 60522</div><div><b>Phone:</b> 877-969-0010 (toll free); 630-990-0010</div><div><b>Fax:</b> 630-990-0246</div><div><b>Email:</b> nationaloffice@compassionatefriends.org</div><div><a href="http://www.compassionatefriends.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.compassionatefriends.org</a></div></li><li class="half_rhythm"><div><b>Helping After Neonatal Death (HAND)</b></div><div>PO Box 341</div><div>Los Gatos CA 95031</div><div><b>Phone:</b> 888-908-HAND (4263)</div><div><b>Email:</b> info@handonline.org</div><div><a href="http://handonline.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.handonline.org</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/dwarfism.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Dwarfism</a></div></li><li class="half_rhythm"><div><b>International Skeletal Dysplasia Registry</b></div><div>UCLA</div><div>615 Charles E. Young Drive</div><div>South Room 410</div><div>Los Angeles CA 90095-7358</div><div><b>Phone:</b> 310-825-8998</div><div><b>Fax:</b> 310-206-5266</div><div><b>Email:</b> Salon@mednet.ucla.edu</div><div><a href="https://www.uclahealth.org/ortho/isdr" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">International Skeletal Dysplasia Registry</a></div></li><li class="half_rhythm"><div><b>Skeletal Dysplasia Network, European (ESDN)</b></div><div>Institute of Genetic Medicine</div><div>Newcastle University, International Centre for Life</div><div>Central Parkway</div><div> Newcastle upon Tyne NE1 3BZ</div><div>United Kingdom</div><div><b>Email:</b> info@esdn.org</div><div><a href="http://www.esdn.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.esdn.org</a></div></li></ul></div><div id="td.Molecular_Genetics"><h2 id="_td_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="td.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Thanatophoric Dysplasia: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1366/table/td.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__td.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_td.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_td.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_td.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_td.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_td.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_td.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_td.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2261" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>FGFR3</i></a></td><td headers="hd_b_td.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2261" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">4p16<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_td.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P22607" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Fibroblast growth factor receptor 3</a></td><td headers="hd_b_td.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/FGFR3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FGFR3 @ LOVD</a></td><td headers="hd_b_td.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=FGFR3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FGFR3</a></td><td headers="hd_b_td.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=FGFR3[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">FGFR3</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="td.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="td.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Thanatophoric Dysplasia (<a href="/omim/134934,187600,187601" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1366/table/td.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__td.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/134934" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">134934</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">FIBROBLAST GROWTH FACTOR RECEPTOR 3; FGFR3</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/187600" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">187600</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">THANATOPHORIC DYSPLASIA, TYPE I; TD1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/187601" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">187601</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">THANATOPHORIC DYSPLASIA, TYPE II; TD2</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>FGFR3</i> is 17 exons in length with transcription initiation located in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 2. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK1366/#td.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Benign variants.</b> See <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">Table 2</a> for known normal variants.</p><p><b>Pathogenic variants</b></p><ul><li class="half_rhythm"><div><b>TD type I.</b>
<i>FGFR3</i> pathogenic variants responsible for the TD type I <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> can be divided into two categories:</div><ul><li class="half_rhythm"><div><b>Missense variants</b> [<a class="bk_pop" href="#td.REF.passosbueno.1999.115">Passos-Bueno et al 1999</a>]. Most of these pathogenic variants create new, unpaired cysteine residues in the protein. The two common variants p.Arg248Cys and p.Tyr373Cys probably account for 60%-80% of TD type I (see <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">Table 2</a>).</div></li><li class="half_rhythm"><div><b>Stop codon variants.</b> These pathogenic variants cause a read-through of the native stop codon, adding a highly hydrophobic alpha helix-containing <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> to the C terminus of the protein. Pathogenic variants that obliterate the stop codon represent 10% or more of TD type I-causing variants (see <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">Table 2</a>).</div></li></ul></li><li class="half_rhythm"><div><b>TD type II.</b> A single <i>FGFR3</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (p.Lys650Glu) has been identified in all cases of TD type II [<a class="bk_pop" href="#td.REF.bellus.2000.1411">Bellus et al 2000</a>]. The lysine residue at position 650 plays a role in stabilizing the activation loop of the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> in an inactive state. Pathogenic variants of this residue destabilize the loop, allowing ligand-independent activation of the tyrosine kinase domain, likely without the need for receptor dimerization at the cell surface [<a class="bk_pop" href="#td.REF.bellus.2000.1411">Bellus et al 2000</a>]. Other pathogenic variants at this position give rise to different phenotypes: p.Lys650Met has been identified in TD type I, and p.Lys650Gln is seen in SADDAN (see <a class="figpopup" href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object" rid-figpopup="figtdTselectedfgfr3variants" rid-ob="figobtdTselectedfgfr3variants">Table 2</a>).</div></li></ul><div id="td.T.selected_fgfr3_variants" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Selected <i>FGFR3</i> Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1366/table/td.T.selected_fgfr3_variants/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__td.T.selected_fgfr3_variants_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_td.T.selected_fgfr3_variants_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype</th><th id="hd_h_td.T.selected_fgfr3_variants_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_td.T.selected_fgfr3_variants_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference<br />Sequences</th></tr></thead><tbody><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Not applicable</b></td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><b>Benign</b></td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.882C&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(=)&#x000a0;<sup>2</sup><br />(N294N)</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_5" rowspan="16" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000142.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000142<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="/entrez/viewer.fcgi?val=NP_000133.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000133<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1953A&#x0003e;G</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.(=)<br />(T651T)</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_1" rowspan="13" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>TD type I</b></td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_2" rowspan="14" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.742C&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg248Cys&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.746C&#x0003e;G</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser249Cys</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1108G&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly370Cys</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1111A&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser371Cys</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1118A&#x0003e;G</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr373Cys&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.1949A&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys650Met</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2420G&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807LeuextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2419T&#x0003e;G</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807GlyextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2419T&#x0003e;C</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807ArgextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2419T&#x0003e;A</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807ArgextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2421A&#x0003e;T</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807CysextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2421A&#x0003e;C</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807CysextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.2421A&#x0003e;G</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ter807TrpextTer101</td></tr><tr><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>TD type II</b></td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_3" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;">c.1948A&#x0003e;G</td><td headers="hd_h_td.T.selected_fgfr3_variants_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys650Glu</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="td.TF.2.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="td.TF.2.2"><p class="no_margin">p.(=) indicates that the protein has not been analyzed but no change is expected.</p></div></dd><dt>3. </dt><dd><div id="td.TF.2.3"><p class="no_margin">Two most common pathogenic variants</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>FGFR3</i> encodes one of four known fibroblast growth factor receptors (FGFRs). All FGFRs share considerable amino acid homology, and the <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> organization is nearly identical to that seen in mice. FGFRs are proteoglycans that function as tyrosine kinases upon binding of a ligand &#x02014; usually one of more than 20 fibroblast growth factors (FGFs) plus proteoglycans containing heparan sulfate [<a class="bk_pop" href="#td.REF.mcintosh.2000.85">McIntosh et al 2000</a>, <a class="bk_pop" href="#td.REF.torley.2002.1096">Torley et al 2002</a>, <a class="bk_pop" href="#td.REF.lievens.2003.17344">Lievens &#x00026; Liboi 2003</a>]. Once a ligand binds, the FGFRs form homo- or heterodimers and undergo phosphorylation of the tyrosine residues in the tyrosine kinase <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>. This is followed by a conformational change that frees intracellular binding sites. Intracellular proteins bind and initiate a signal cascade that usually influences protein activation or gene expression [<a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>, <a class="bk_pop" href="#td.REF.torley.2002.1096">Torley et al 2002</a>]. Multiple pathways have been implicated, including ras/MAPK/ERK, P13/Akt, PLC-&#x003b3;, and STAT1 [<a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>, <a class="bk_pop" href="#td.REF.torley.2002.1096">Torley et al 2002</a>]. After activation, the complex is internalized for signal downregulation. This is accomplished via one of two pathways [<a class="bk_pop" href="#td.REF.lievens.2006.783">Lievens et al 2006</a>]: ubiquitination and degradation of the activated FGFR or feedback from the end targets (namely ERK) through the docking protein FRS2&#x003b1;.</p><p>FGFR3 consists of an extracellular signal peptide, three immunoglobulin-like domains (IgI, IgII, and IgIII) with an acid box between IgI and IgII, a transmembrane <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a>, and a split intracellular tyrosine kinase domain [<a class="bk_pop" href="#td.REF.hyland.2003.157">Hyland et al 2003</a>]. Ligand binding occurs between IgII and IgIII [<a class="bk_pop" href="#td.REF.mcintosh.2000.85">McIntosh et al 2000</a>]. The normal function of <i>FGFR3</i> is to serve as a negative regulator of bone growth during ossification [<a class="bk_pop" href="#td.REF.legeaimallet.1998.13007">Legeai-Mallet et al 1998</a>, <a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>]. Mice with knockout variants of <i>Fgfr3</i> are overgrown with elongated vertebrae and long femurs and tails. The growth plates of the long bones are expanded [<a class="bk_pop" href="#td.REF.mcintosh.2000.85">McIntosh et al 2000</a>, <a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>]. Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> of exons 8 and 9 has been documented, with such diversity conferring the capacity for differential expression and binding of multiple ligands [<a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>]. Three reported <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> of FGFR3 include: the native protein, an intermediate intracellular membrane-associated glycoprotein, and a mature glycoprotein [<a class="bk_pop" href="#td.REF.lievens.2003.17344">Lievens &#x00026; Liboi 2003</a>].</p><p>FGFR3 is expressed in a spatial- and temporal-specific pattern during embryogenesis [<a class="bk_pop" href="#td.REF.mcintosh.2000.85">McIntosh et al 2000</a>]. The highest levels of expression occur in cartilage and the central nervous system [<a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>]. FGFR3 is also expressed in the dermis and epidermis [<a class="bk_pop" href="#td.REF.mcintosh.2000.85">McIntosh et al 2000</a>, <a class="bk_pop" href="#td.REF.torley.2002.1096">Torley et al 2002</a>].</p><p>The FGFR3 signaling pathway is activated in several cancers, including bladder and cervical cancer and multiple myeloma. <a class="bk_pop" href="#td.REF.meyer.2004.28450">Meyer et al [2004]</a> identified FGFR3 in complex with Pyk2, a focal adhesion kinase known to regulate apoptosis in multiple myeloma cells and to activate Stat5B. FGFR3 phosphorylates Pyk2 and activates a signaling pathway without recruitment of proteins from the Src family (which are normally recruited by Pyk2 in the absence of FGFR3). Hyperactivated FGFR3 (i.e., pathogenic variants similar to those causing TD) causes hyperphosphorylation of Pyk2. FGFR3 may also sequester Pyk2 from Shp2, which normally functions to decrease Pyk2 phosphorylation and downregulate Pyk2 signaling. Both FGFR3 and Pyk2 may work in concert to maximally activate Stat5B [<a class="bk_pop" href="#td.REF.meyer.2004.28450">Meyer et al 2004</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Pathogenic variants in <i>FGFR3</i> are <a class="def" href="/books/n/gene/glossary/def-item/gain-of-function/">gain-of-function</a> variants that produce a constitutively active protein capable of initiating intracellular signal pathways in the absence of ligand binding [<a class="bk_pop" href="#td.REF.baitner.2000.594">Baitner et al 2000</a>, <a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>]. This activation leads to premature differentiation of proliferative chondrocytes into pre-hypertrophic chondrocytes and, ultimately, to premature maturation of the bone [<a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>, <a class="bk_pop" href="#td.REF.legeaimallet.2004.26">Legeai-Mallet et al 2004</a>]. The mechanism for other clinical findings in TD type I and TD type II (CNS and dermal abnormalities) is less clear. All reported pathogenic variants cause constitutive activation through the creation of new, unpaired cysteine residues that induce ligand-independent dimerization [<a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>], activation of the tyrosine kinase loop [<a class="bk_pop" href="#td.REF.tavormina.1999.722">Tavormina et al 1999</a>, <a class="bk_pop" href="#td.REF.cohen.2002.304">Cohen 2002</a>], or creation of an elongated protein through destruction of the native stop codon.</p><p>Studies have shown that the level of ligand-independent tyrosine kinase activity conferred by different <i>FGFR3</i> pathogenic variants is correlated with the severity of disorganization of endochondral ossification and, therefore, with the skeletal <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#td.REF.bellus.1999.53">Bellus et al 1999</a>, <a class="bk_pop" href="#td.REF.bellus.2000.1411">Bellus et al 2000</a>].</p><p>The p.Lys650Glu <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> causing thanatophoric dysplasia type II has been shown to cause accumulation of intermediate, activated forms of FGFR3 in the endoplasmic reticulum [<a class="bk_pop" href="#td.REF.lievens.2003.17344">Lievens &#x00026; Liboi 2003</a>]. This immature, cellular FGFR3 is able to signal through an FRS2&#x003b1;-independent pathway (via the JAK/STAT pathway) that is then not subject to FRS2&#x003b1;-mediated downregulation [<a class="bk_pop" href="#td.REF.lievens.2006.783">Lievens et al 2006</a>].</p></div><div id="td.References"><h2 id="_td_References_">References</h2><div id="td.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="td.REF.arikawahirasawa.2001.254">Arikawa-Hirasawa E, Wilcox WR, Yamada Y. Dyssegmental dysplasia, Silverman-Handmaker type: unexpected role of perlecan in cartilage development. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">106</span>:254–7.</span> [<a href="/pubmed/11891676" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11891676</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.baitner.2000.594">Baitner AC, Maurer SG, Gruen MB, Di Cesare PE. The genetic basis of the osteochondrodysplasias. <span><span class="ref-journal">J Pediatr Orthop. </span>2000;<span class="ref-vol">20</span>:594–605.</span> [<a href="/pubmed/11008738" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11008738</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.barbosabuck.2012.1038">Barbosa-Buck CO, Orioli IM, Dutra MG, Lopez-Camelo J, Castilla EE, Cavalcanti DP. Clinical epidemiology of skeletal dysplasias in South America. <span><span class="ref-journal">Am J Med Genet Part A. </span>2012;<span class="ref-vol">158A</span>:1038–45.</span> [<a href="/pubmed/22407836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22407836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.bellus.1999.53">Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko O, Jabs EW, Curry CJ, Wilcox WR, Lachman RS, Rimoin DL, Francomano CA. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">85</span>:53–65.</span> [<a href="/pubmed/10377013" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10377013</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.bellus.2000.1411">Bellus GA, Spector EB, Speiser PW, Weaver CA, Garber AT, Bryke CR, Israel J, Rosengren SS, Webster MK, Donoghue DJ, Francomano CA. Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. <span><span class="ref-journal">Am J Hum Genet. </span>2000;<span class="ref-vol">67</span>:1411–21.</span> [<a href="/pmc/articles/PMC1287918/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1287918</span></a>] [<a href="/pubmed/11055896" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11055896</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.brodie.1999.476">Brodie SG, Kitoh H, Lachman RS, Nolasco LM, Mekikian PB, Wilcox WR. Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by FGFR3 mutations. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">84</span>:476–80.</span> [<a href="/pubmed/10360402" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10360402</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.camera.2001.277">Camera G, Baldi M, Strisciuglio G, Concolino D, Mastroiacovo P, Baffico M. Occurrence of thanatophoric dysplasia type I (R248C) and hypochondroplasia (N540K) mutations in two patients with achondroplasia phenotype. <span><span class="ref-journal">Am J Med Genet. </span>2001;<span class="ref-vol">104</span>:277–81.</span> [<a href="/pubmed/11754059" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11754059</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.chen.2001.89">Chen CP, Chern SR, Shih JC, Wang W, Yeh LF, Chang TY, Tzen CY. Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia. <span><span class="ref-journal">Prenat Diagn. </span>2001;<span class="ref-vol">21</span>:89–95.</span> [<a href="/pubmed/11241532" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11241532</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.cohen.2002.304">Cohen MM Jr. Some chondrodysplasias with short limbs: molecular perspectives. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">112</span>:304–13.</span> [<a href="/pubmed/12357475" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12357475</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.de_biasio.2005.426">De Biasio P, Ichim IB, Scarso E, Baldi M, Barban A, Venturini PL. Thanatophoric dysplasia type I presenting with increased nuchal translucency in the first trimester. <span><span class="ref-journal">Prenat Diagn. </span>2005;<span class="ref-vol">25</span>:426–8.</span> [<a href="/pubmed/15906417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15906417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.de_biasio.2000.835">De Biasio P, Prefumo F, Baffico M, Baldi M, Priolo M, Lerone M, Toma P, Venturini PL. Sonographic and molecular diagnosis of thanatophoric dysplasia type I at 18 weeks of gestation. <span><span class="ref-journal">Prenat Diagn. </span>2000;<span class="ref-vol">20</span>:835–7.</span> [<a href="/pubmed/11038465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11038465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.donnelly.2010.114">Donnelly DE, McConnell V, Paterson A, Morrison PJ. The prevalence of thanatophoric dysplasia and lethal osteogenesis imperfecta type II in Northern Ireland - a complete population study. <span><span class="ref-journal">Ulster Med J. </span>2010;<span class="ref-vol">79</span>:114–8.</span> [<a href="/pmc/articles/PMC3284715/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3284715</span></a>] [<a href="/pubmed/22375084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22375084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.ferreira.2004.241">Ferreira A, Matias A, Brandao O, Montenegro N. Nuchal translucency and ductus venosus blood flow as early sonographic markers of thanatophoric dysplasia. A case report. <span><span class="ref-journal">Fetal Diagn Ther. </span>2004;<span class="ref-vol">19</span>:241–5.</span> [<a href="/pubmed/15067234" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15067234</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.hyland.2003.157">Hyland VJ, Robertson SP, Flanagan S, Savarirayan R, Roscioli T, Masel J, Hayes M, Glass IA. Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. <span><span class="ref-journal">Am J Med Genet A. </span>2003;<span class="ref-vol">120A</span>:157–68.</span> [<a href="/pubmed/12833394" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12833394</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.khalil.2011.115">Khalil A, Pajkrt E, Chitty LS. Early prenatal diagnosis of skeletal anomalies. <span><span class="ref-journal">Prenat Diagn. </span>2011;<span class="ref-vol">31</span>:115–24.</span> [<a href="/pubmed/21210484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21210484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.krakow.2008.1917">Krakow D, Alanay Y, Rimoin LP, Lin V, Wilcox WR, Lachman RS, Rimoin DL. Evaluation of prenatal-onset osteochondrodysplasias by ultrasonography: a retrospective and prospective analysis. <span><span class="ref-journal">Am J Med Genet A. </span>2008;<span class="ref-vol">146A</span>:1917–24.</span> [<a href="/pmc/articles/PMC2713784/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2713784</span></a>] [<a href="/pubmed/18627037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18627037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.lee.2002.113">Lee SH, Cho JY, Song MJ, Min JY, Han BH, Lee YH, Cho BJ, Kim SH. Fetal musculoskeletal malformations with a poor outcome: ultrasonographic, pathologic, and radiographic findings. <span><span class="ref-journal">Korean J Radiol. </span>2002;<span class="ref-vol">3</span>:113–24.</span> [<a href="/pmc/articles/PMC2713834/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2713834</span></a>] [<a href="/pubmed/12087201" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12087201</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.legeaimallet.1998.13007">Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J. Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. <span><span class="ref-journal">J Biol Chem. </span>1998;<span class="ref-vol">273</span>:13007–14.</span> [<a href="/pubmed/9582336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9582336</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.legeaimallet.2004.26">Legeai-Mallet L, Benoist-Lasselin C, Munnich A, Bonaventure J. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. <span><span class="ref-journal">Bone. </span>2004;<span class="ref-vol">34</span>:26–36.</span> [<a href="/pubmed/14751560" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14751560</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.lemyre.1999.185">Lemyre E, Azouz EM, Teebi AS, Glanc P, Chen MF. Bone dysplasia series. Achondroplasia, hypochondroplasia and thanatophoric dysplasia: review and update. <span><span class="ref-journal">Can Assoc Radiol J. </span>1999;<span class="ref-vol">50</span>:185–97.</span> [<a href="/pubmed/10405653" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10405653</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.lievens.2003.17344">Lievens PM, Liboi E. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. <span><span class="ref-journal">J Biol Chem. </span>2003;<span class="ref-vol">278</span>:17344–9.</span> [<a href="/pubmed/12624096" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12624096</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.lievens.2006.783">Lievens PM, Roncador A, Liboi E. K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways. <span><span class="ref-journal">J Mol Biol. </span>2006;<span class="ref-vol">357</span>:783–92.</span> [<a href="/pubmed/16476447" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16476447</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.macdonald.1989.508">MacDonald IM, Hunter AG, MacLeod PM, MacMurray SB. Growth and development in thanatophoric dysplasia. <span><span class="ref-journal">Am J Med Genet. </span>1989;<span class="ref-vol">33</span>:508–12.</span> [<a href="/pubmed/2596513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2596513</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.mansour.1995.415">Mansour S, Hall CM, Pembrey ME, Young ID. A clinical and genetic study of campomelic dysplasia. <span><span class="ref-journal">J Med Genet. </span>1995;<span class="ref-vol">32</span>:415–20.</span> [<a href="/pmc/articles/PMC1050480/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1050480</span></a>] [<a href="/pubmed/7666392" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7666392</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.marquisnicholson.2013.80">Marquis-Nicholson R, Aftimos S, Love DR. Molecular analysis of a case of thanatophoric dysplasia reveals two de novo FGFR3 missense mutations located in cis. <span><span class="ref-journal">Sultan Qaboos Univ Med J. </span>2013 2013 Feb;<span class="ref-vol">13</span>:80–7.</span> [<a href="/pmc/articles/PMC3616804/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3616804</span></a>] [<a href="/pubmed/23573386" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23573386</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.mart_nezfr_as.2011.197">Mart&#x000ed;nez-Fr&#x000ed;as ML, Eg&#x000fc;&#x000e9;s X, Puras A, Hualde J, de Frutos CA, Bermejo E, Nieto MA, Mart&#x000ed;nez S. Thanatophoric dysplasia type II with encephalocele and semilobar holoprosencephaly: Insights into its pathogenesis. <span><span class="ref-journal">Am J Med Genet A. </span>2011;<span class="ref-vol">155A</span>:197–202.</span> [<a href="/pubmed/21204232" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21204232</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.mcintosh.2000.85">McIntosh I, Bellus GA, Jab EW. The pleiotropic effects of fibroblast growth factor receptors in mammalian development. <span><span class="ref-journal">Cell Struct Funct. </span>2000;<span class="ref-vol">25</span>:85–96.</span> [<a href="/pubmed/10885578" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10885578</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.meyer.2004.28450">Meyer AN, Gastwirt RF, Schlaepfer DD, Donoghue DJ. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation. <span><span class="ref-journal">J Biol Chem. </span>2004;<span class="ref-vol">279</span>:28450–7.</span> [<a href="/pubmed/15105428" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15105428</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.neumann.2003.786">Neumann L, Kunze J, Uhl M, Stover B, Zabel B, Spranger J. Survival to adulthood and dominant inheritance of platyspondylic skeletal dysplasia, Torrance-Luton type. <span><span class="ref-journal">Pediatr Radiol. </span>2003;<span class="ref-vol">33</span>:786–90.</span> [<a href="/pubmed/12961049" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12961049</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.nishimura.2004.75">Nishimura G, Nakashima E, Mabuchi A, Shimamoto K, Shimamoto T, Shimao Y, Nagai T, Yamaguchi T, Kosaki R, Ohashi H, Makita Y, Ikegawa S. Identification of COL2A1 mutations in platyspondylic skeletal dysplasia, Torrance type. <span><span class="ref-journal">J Med Genet. </span>2004;<span class="ref-vol">41</span>:75–9.</span> [<a href="/pmc/articles/PMC1757240/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1757240</span></a>] [<a href="/pubmed/14729840" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14729840</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.pannier.2009.1296">Pannier S, Martinovic J, Heuertz S, Delezoide AL, Munnich A, Schibler L, Serre V, Legeai-Mallet L. Thanatophoric dysplasia caused by double missense FGFR3 mutations. <span><span class="ref-journal">Am J Med Genet A. </span>2009;<span class="ref-vol">149A</span>:1296–301.</span> [<a href="/pubmed/19449430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19449430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.parilla.2003.255">Parilla BV, Leeth EA, Kambich MP, Chillis P, MacGregor SN. Antenatal detection of skeletal dysplasias. <span><span class="ref-journal">J Ultrasound Med. </span>2003;<span class="ref-vol">22</span>:255–8.</span> [<a href="/pubmed/12636325" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12636325</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.passosbueno.1999.115">Passos-Bueno MR, Wilcox WR, Jabs EW, Sertie AL, Alonso LG, Kitoh H. Clinical spectrum of fibroblast growth factor receptor mutations. <span><span class="ref-journal">Hum Mutat. </span>1999;<span class="ref-vol">14</span>:115–25.</span> [<a href="/pubmed/10425034" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10425034</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.rohmann.2006.414">Rohmann E, Brunner HG, Kayserili H, Uyguner O, Nurnberg G, Lew ED, Dobbie A, Eswarakumar VP, Uzumcu A, Ulubil-Emeroglu M, Leroy JG, Li Y, Becker C, Lehnerdt K, Cremers CW, Yuksel-Apak M, Nurnberg P, Kubisch C, Schlessinger J, van Bokhoven H, Wollnik B. Mutations in different components of FGF signaling in LADD syndrome. <span><span class="ref-journal">Nat Genet. </span>2006;<span class="ref-vol">38</span>:414–7.</span> [<a href="/pubmed/16501574" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16501574</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.schramm.2009.160">Schramm T, Gloning KP, Minderer S, Daumer-Haas C, H&#x000f6;rtnagel K, Nerlich A, Tutschek B. Prenatal sonographic diagnosis of skeletal dysplasias. <span><span class="ref-journal">Ultrasound Obstet Gynecol. </span>2009;<span class="ref-vol">34</span>:160–70.</span> [<a href="/pubmed/19548204" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19548204</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.takagi.2012.247">Takagi M, Kaneko-Schmitt S, Suzumori N, Nishimura G, Hasegawa T. Atypical achondroplasia due to somatic mosaicism for the common thanatophoric dysplasia mutation R248C. <span><span class="ref-journal">Am J Med Genet Part A. </span>2012;<span class="ref-vol">158A</span>:247–50.</span> [<a href="/pubmed/22106050" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22106050</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.tavormina.1999.722">Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donoghue DJ, Thompson LM, Francomano CA. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:722–31.</span> [<a href="/pmc/articles/PMC1377789/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377789</span></a>] [<a href="/pubmed/10053006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10053006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.thompson.2011.92">Thompson DR, Browd SR, Sangar&#x000e9; Y, Rowell JC, Slimp JC, Haberkern CM. Anesthetic management of an infant with thanatophoric dysplasia for suboccipital decompression. <span><span class="ref-journal">Paediatr Anaesth. </span>2011;<span class="ref-vol">21</span>:92–4.</span> [<a href="/pubmed/21155935" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21155935</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.tonni.2010.314">Tonni G, Azzoni D, Ventura A, Ferrari B, Felice CD, Baldi M. Thanatophoric dysplasia type I associated with increased nuchal translucency in the first trimester: Early prenatal diagnosis using combined ultrasonography and molecular biology. <span><span class="ref-journal">Fetal Pediatr Pathol. </span>2010;<span class="ref-vol">29</span>:314–22.</span> [<a href="/pubmed/20704477" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20704477</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.torley.2002.1096">Torley D, Bellus GA, Munro CS. Genes, growth factors and acanthosis nigricans. <span><span class="ref-journal">Br J Dermatol. </span>2002;<span class="ref-vol">147</span>:1096–101.</span> [<a href="/pubmed/12452857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12452857</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.wilcox.1998.274">Wilcox WR, Tavormina PL, Krakow D, Kitoh H, Lachman RS, Wasmuth JJ, Thompson LM, Rimoin DL. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. <span><span class="ref-journal">Am J Med Genet. </span>1998;<span class="ref-vol">78</span>:274–81.</span> [<a href="/pubmed/9677066" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9677066</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="td.REF.zankl.2005.61">Zankl A, Neumann L, Ignatius J, Nikkels P, Schrander-Stumpel C, Mortier G, Omran H, Wright M, Hilbert K, Bonaf&#x000e9; L, Spranger J, Zabel B, Superti-Furga A. Dominant negative mutations in the C-propeptide of COL2A1 cause platyspondylic lethal skeletal dysplasia, torrance type, and define a novel subfamily within type 2 collagenopathies. <span><span class="ref-journal">Am J Med Genet A. </span>2005;<span class="ref-vol">133A</span>:61–7.</span> [<a href="/pubmed/15643621" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15643621</span></a>]</div></li></ul></div></div><div id="td.Chapter_Notes"><h2 id="_td_Chapter_Notes_">Chapter Notes</h2><div id="td.Acknowledgments"><h3>Acknowledgments</h3><p>The authors wish to thank Julie Hoover-Fong MD, Clinical Director of the Greenberg Center for Skeletal Dysplasias at Johns Hopkins University, for her clinical insight.</p></div><div id="td.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>12 September 2013 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>30 September 2008 (cg) Comprehensive update posted live</div></li><li class="half_rhythm"><div>7 July 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>21 May 2004 (me) Review posted live</div></li><li class="half_rhythm"><div>27 February 2004 (bk, gc) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1366</span><span class="label">PMID: <a href="/pubmed/20301540" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301540</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/tetra-amelia/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/trma/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1366&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1366/?report=reader">PubReader</a></li><li><a href="/books/NBK1366/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1366" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1366" style="display:none" title="Cite this Page"><div class="bk_tt">Karczeski B, Cutting GR. Thanatophoric Dysplasia. 2004 May 21 [Updated 2013 Sep 12]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1366/pdf/Bookshelf_NBK1366.pdf">PDF version of this page</a> (458K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#td.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#td.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#td.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#td.Genetically_Related_Allelic_Disorders" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#td.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#td.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#td.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#td.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#td.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#td.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#td.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2261[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">FGFR3</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1366+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1487440" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1487440" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1487440" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1487440" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23573386" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Molecular Analysis of a Case of Thanatophoric Dysplasia Reveals Two de novo FGFR3 Missense Mutations located in cis.</a><span class="source">[Sultan Qaboos Univ Med J. 2013]</span><div class="brieflinkpop offscreen_noflow">Molecular Analysis of a Case of Thanatophoric Dysplasia Reveals Two de novo FGFR3 Missense Mutations located in cis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Marquis-Nicholson R, Aftimos S, Love DR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Sultan Qaboos Univ Med J. 2013 Feb; 13(1):80-7. Epub 2013 Feb 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301331" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Achondroplasia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Achondroplasia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pauli RM, Legare JM. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24075385" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II.</a><span class="source">[Taiwan J Obstet Gynecol. 2013]</span><div class="brieflinkpop offscreen_noflow">Rapid detection of K650E mutation in FGFR3 using uncultured amniocytes in a pregnancy affected with fetal cloverleaf skull, occipital pseudoencephalocele, ventriculomegaly, straight short femurs, and thanatophoric dysplasia type II.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chen CP, Chang TY, Lin MH, Chern SR, Su JW, Wang W. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Taiwan J Obstet Gynecol. 2013 Sep; 52(3):420-5. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/11241532" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia.</a><span class="source">[Prenat Diagn. 2001]</span><div class="brieflinkpop offscreen_noflow">Prenatal diagnosis and genetic analysis of type I and type II thanatophoric dysplasia.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Chen CP, Chern SR, Shih JC, Wang W, Yeh LF, Chang TY, Tzen CY. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Prenat Diagn. 2001 Feb; 21(2):89-95. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301650" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypochondroplasia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hypochondroplasia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bober MB, Bellus GA, Nikkel SM, Tiller GE. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301540" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301540" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040f1975f66d18aab67576">Thanatophoric Dysplasia - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Thanatophoric Dysplasia - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:38:34-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C471AE0409E6100000000023500C8&amp;ncbi_session=CE8C471AE040F191_0565SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1366%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1366&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1366/&amp;ncbi_pagename=Thanatophoric Dysplasia - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C471AE040F191_0565SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>